NASDAQ : CRNX
Crinetics Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 84.95 USD (At close: Aug 31, 2026) · Market cap 9.01B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of 42.16M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 42.16M | 7.70M | 1.04M | 4.01M | 4.74M | 1.08M |
| Cost of Revenue | 376.88M | 333.13M | 240.16M | 168.53M | 130.22M | 84.25M |
| Gross Profit | -334.72M | -325.44M | -239.12M | -164.51M | -125.49M | -83.18M |
| Selling, General & Admin | 214.37M | 191.33M | 99.74M | 58.09M | 42.39M | 24.52M |
| Operating Expenses | 214.37M | 191.33M | 99.74M | 58.09M | 42.39M | 24.52M |
| Operating Income | -549.09M | -516.77M | -338.85M | -222.61M | -167.88M | -107.70M |
| Interest & Investment Income | 48.39M | 51.99M | 41.44M | 13.44M | 4.32M | 157.00K |
| Earnings From Equity Investments | -470.00K | -5.20M | -1.01M | |||
| Currency Exchange Gain (Loss) | -107.00K | |||||
| Other Non Operating Income (Expenses) | -728.00K | -357.00K | -519.00K | -159.00K | 657.00K | 11.00K |
| Pretax Income | -501.43M | -465.14M | -298.41M | -214.53M | -163.92M | -107.64M |
| Income Tax Expense | 180.00K | 180.00K | ||||
| Net Income | -501.61M | -465.32M | -298.41M | -214.53M | -163.92M | -107.64M |
| Net Income to Common | -501.61M | -465.32M | -298.41M | -214.53M | -163.92M | -107.64M |
| Shares Outstanding (Basic) | 99.75M | 94.06M | 80.78M | 58.07M | 51.98M | 38.44M |
| Shares Outstanding (Diluted) | 99.75M | 94.06M | 80.78M | 58.07M | 51.98M | 38.44M |
| EPS (Basic) | -5.03 | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 |
| EPS (Diluted) | -5.03 | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 |
| Free Cash Flow | -425.18M | -383.68M | -234.04M | -173.29M | -116.86M | -89.02M |
| Free Cash Flow Per Share | -4.26 | -4.08 | -2.90 | -2.98 | -2.25 | -2.32 |
| Operating Margin | -1,302.52% | -6,714.77% | -32,613.47% | -5,547.17% | -3,544.06% | -9,990.91% |
| Profit Margin | -1,189.88% | -6,046.22% | -28,720.69% | -5,345.85% | -3,460.38% | -9,985.25% |
| Free Cash Flow Margin | -1,008.58% | -4,985.50% | -22,525.31% | -4,318.12% | -2,466.98% | -8,258.26% |
| EBITDA | -544.85M | -512.88M | -336.07M | -221.51M | -166.90M | -106.78M |
| D&A For EBITDA | 4.24M | 3.89M | 2.79M | 1.10M | 983.00K | 922.00K |
| EBIT | -549.09M | -516.77M | -338.85M | -222.61M | -167.88M | -107.70M |
| Revenue as Reported | 42.16M | 7.70M | 1.04M | 4.01M | ||
| Advertising Expenses | 16.90M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 55.50M | 101.54M | 264.55M | 54.90M | 32.67M | 200.69M |
| Short-Term Investments | 1.15B | 926.35M | 1.09B | 503.66M | 301.75M | 133.01M |
| Cash & Short-Term Investments | 1.21B | 1.03B | 1.35B | 558.55M | 334.43M | 333.71M |
| Accounts Receivable | 11.96M | 592.00K | ||||
| Other Receivables | 9.26M | 2.90M | 1.48M | |||
| Receivables | 11.96M | 592.00K | 9.26M | 2.90M | 1.48M | |
| Inventory | 3.49M | 2.02M | ||||
| Prepaid Expenses | 23.14M | 17.84M | 20.82M | 4.56M | 3.51M | 7.20M |
| Restricted Cash | 500.00K | |||||
| Other Current Assets | 1.78M | 4.36M | 2.34M | |||
| Total Current Assets | 1.24B | 1.05B | 1.38B | 574.15M | 345.18M | 344.72M |
| Property, Plant & Equipment | 52.18M | 54.79M | 55.58M | 57.43M | 4.99M | 4.72M |
| Long-Term Investments | 2.00M | 470.00K | 1.01M | |||
| Other Long-Term Assets | 25.34M | 21.13M | 3.63M | 3.30M | 2.01M | 568.00K |
| Total Assets | 1.32B | 1.13B | 1.43B | 635.35M | 352.18M | 351.01M |
| Accounts Payable | 13.25M | 22.61M | 5.85M | 6.55M | 6.88M | 3.42M |
| Accrued Expenses | 58.41M | 54.74M | 44.50M | 27.35M | 17.19M | 11.63M |
| Current Portion of Leases | 6.58M | 6.49M | 7.15M | 4.17M | 1.05M | 939.00K |
| Current Unearned Revenue | 1.67M | 1.24M | 2.18M | 2.06M | 2.24M | |
| Other Current Liabilities | 3.82M | 359.00K | ||||
| Total Current Liabilities | 79.92M | 85.07M | 59.68M | 43.94M | 27.72M | 15.99M |
| Long-Term Leases | 40.61M | 42.05M | 44.57M | 47.55M | 2.02M | 3.07M |
| Long-Term Unearned Revenue | 3.46M | 3.81M | 4.70M | 4.75M | 6.10M | |
| Other Long-Term Liabilities | 5.93M | 3.24M | 829.00K | 2.00K | ||
| Total Liabilities | 129.92M | 134.17M | 109.79M | 96.25M | 35.85M | 19.07M |
| Common Stock | 2.86B | 2.41B | 2.28B | 1.19B | 759.43M | 607.58M |
| Retained Earnings | -1.67B | -1.42B | -952.11M | -653.70M | -439.17M | -275.25M |
| Comprehensive Income & Other | -4.27M | 1.75M | 963.00K | 977.00K | -3.93M | -382.00K |
| Total Common Equity | 1.19B | 992.08M | 1.32B | 539.11M | 316.33M | 331.94M |
| Shareholders' Equity | 1.19B | 992.08M | 1.32B | 539.11M | 316.33M | 331.94M |
| Total Liabilities & Equity | 1.32B | 1.13B | 1.43B | 635.35M | 352.18M | 351.01M |
| Total Debt | 47.19M | 48.54M | 51.72M | 51.73M | 3.08M | 4.01M |
| Net Cash (Debt) | 1.16B | 979.35M | 1.30B | 506.83M | 331.35M | 329.69M |
| Net Cash Per Share | 11.61 | 10.41 | 16.12 | 8.73 | 6.37 | 8.58 |
| Filing Date Shares Outstanding | 106.07M | 104.71M | 93.05M | 69.60M | 53.91M | 47.78M |
| Total Common Shares Outstanding | 105.81M | 95.58M | 92.93M | 68.17M | 53.88M | 47.60M |
| Working Capital | 1.16B | 963.27M | 1.32B | 530.21M | 317.46M | 328.73M |
| Book Value Per Share | 11.27 | 10.38 | 14.26 | 7.91 | 5.87 | 6.97 |
| Tangible Book Value | 1.19B | 992.08M | 1.32B | 539.11M | 316.33M | 331.94M |
| Tangible Book Value Per Share | 11.27 | 10.38 | 14.26 | 7.91 | 5.87 | 6.97 |
| Machinery | 13.04M | 12.24M | 7.90M | 6.11M | 4.07M | 2.79M |
| Leasehold Improvements | 10.14M | 10.00M | 11.90M | 9.84M | 3.52M | 3.52M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -501.61M | -465.32M | -298.41M | -214.53M | -163.92M | -107.64M |
| Depreciation & Amortization | 4.24M | 3.89M | 2.79M | 1.10M | 983.00K | 922.00K |
| Loss (Gain) From Sale of Assets | 28.00K | 50.00K | 51.00K | 6.00K | ||
| Loss (Gain) From Sale of Investments | -10.58M | -15.43M | -14.93M | -6.27M | 34.00K | 422.00K |
| Loss (Gain) on Equity Investments | 470.00K | 5.20M | 1.01M | |||
| Stock-Based Compensation | 98.98M | 91.02M | 69.39M | 40.94M | 28.27M | 17.35M |
| Other Operating Activities | 2.79M | 3.01M | 3.04M | -790.00K | -194.00K | -739.00K |
| Change in Accounts Receivable | -11.96M | -592.00K | ||||
| Change in Inventory | -3.29M | -2.02M | ||||
| Change in Accounts Payable | 15.05M | 28.98M | 13.32M | 12.36M | 10.99M | 6.29M |
| Change in Unearned Revenue | -763.00K | -1.83M | 74.00K | -1.53M | 8.34M | |
| Change in Other Net Operating Assets | -15.42M | -19.69M | -5.98M | -5.07M | -723.00K | -5.20M |
| Operating Cash Flow | -422.51M | -377.92M | -230.19M | -168.60M | -115.20M | -88.59M |
| Capital Expenditures | -2.66M | -5.76M | -3.84M | -4.69M | -1.66M | -436.00K |
| Investment in Securities | -1.49M | 179.67M | -570.97M | -195.72M | -172.32M | -56.05M |
| Investing Cash Flow | -4.15M | 173.91M | -574.82M | -200.41M | -173.98M | -56.48M |
| Issuance of Common Stock | 428.50M | 40.61M | 1.03B | 391.78M | 129.72M | 265.64M |
| Other Financing Activities | -578.00K | -14.98M | -541.00K | -7.76M | -12.96M | |
| Financing Cash Flow | 427.92M | 40.61M | 1.01B | 391.24M | 121.96M | 252.68M |
| Foreign Exchange Rate Adjustments | 18.00K | -106.00K | ||||
| Net Cash Flow | 1.27M | -163.51M | 209.65M | 22.22M | -167.22M | 107.61M |
| Free Cash Flow | -425.18M | -383.68M | -234.04M | -173.29M | -116.86M | -89.02M |
| Free Cash Flow Margin | -1,008.58% | -4,985.50% | -22,525.31% | -4,318.12% | -2,466.98% | -8,258.26% |
| Free Cash Flow Per Share | -4.26 | -4.08 | -2.90 | -2.98 | -2.25 | -2.32 |
| Levered Free Cash Flow | -248.76M | -206.91M | -136.41M | -93.53M | -62.51M | -48.47M |
| Unlevered Free Cash Flow | -248.76M | -206.91M | -136.41M | -93.53M | -62.51M | -48.47M |
| Change in Working Capital | -16.38M | 4.84M | 7.41M | 5.75M | 18.61M | 1.10M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 9.01B | 4.42B | 4.74B | 2.38B | 984.73M | 1.34B |
| Enterprise Value | 7.85B | 3.37B | 3.93B | 1.87B | 619.69M | 1.15B |
| Last Close Price | 84.95 | 46.55 | 51.13 | 35.58 | 18.30 | 28.41 |
| PS Ratio | 213.74 | 573.96 | 4,563.69 | 592.25 | 207.88 | 1,242.80 |
| PB Ratio | 7.54 | 4.45 | 3.58 | 4.41 | 3.11 | 4.04 |
| P/TBV Ratio | 7.56 | 4.45 | 3.58 | 4.41 | 3.11 | 4.04 |
| EV/Sales Ratio | 186.25 | 438.42 | 3,783.97 | 467.04 | 130.82 | 1,067.38 |
| Debt / Equity Ratio | 0.04 | 0.05 | 0.04 | 0.10 | 0.01 | 0.01 |
| Net Debt / Equity Ratio | -0.97 | -0.99 | -0.98 | -0.94 | -1.05 | -0.99 |
| Net Debt / EBITDA Ratio | 2.13 | 1.91 | 3.88 | 2.29 | 1.99 | 3.09 |
| Net Debt / FCF Ratio | 2.73 | 2.55 | 5.57 | 2.92 | 2.83 | 3.70 |
| Asset Turnover | 0.03 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Quick Ratio | 15.24 | 12.09 | 22.69 | 12.92 | 12.17 | 20.95 |
| Current Ratio | 15.57 | 12.32 | 23.05 | 13.07 | 12.45 | 21.55 |
| Return on Equity (ROE) | -42.45% | -40.17% | -32.02% | -50.16% | -50.57% | -42.98% |
| Return on Assets (ROA) | -26.28% | -25.22% | -20.46% | -28.18% | -29.84% | -25.19% |
| Return on Capital Employed (ROCE) | -44.20% | -49.60% | -24.60% | -37.60% | -51.70% | -32.10% |
| Earnings Yield | -5.57% | -10.53% | -6.29% | -9.03% | -16.65% | -8.04% |
| FCF Yield | -4.72% | -8.69% | -4.94% | -7.29% | -11.87% | -6.64% |
| Buyback Yield / Dilution | -11.25% | -16.43% | -39.11% | -11.71% | -35.24% | -26.24% |